Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171448
Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Resum
We read with some concern the recent article in Genetics in Medicine reporting a high lifetime risk of breast cancer in pathogenic variant (PV) carriers for PMS2 and MSH6 (ref. 1). Although the reported odds ratios for breast cancer were given as MSH6 (2.11; 95% confidence interval [CI] = 1.56–2.86) and PMS2 (2.92; 95% CI = 2.17–3.92) the cumulative risks to age 60 were given as 31.1% (95% CI, 21.9–40.7) and 37.7% (95% CI, 27.5–47.8) respectively. These are equivalent to UK National Institute for Health and Care Excellence (NICE) defined high lifetime risks. These two analyses are inaccurate given that the risk of breast cancer to the age of 60 years in the UK and United States is 5–6%. Therefore, if the risks from incidence ratios and Kaplan–Meier were equivalent, the odds ratios would be over 6-fold for PMS2 and >5-fold for MSH6.
Descripció
Matèries
Matèries (anglès)
Citació
Citació
EVANS, D. gareth, WOODWARD, E. r., LALLOO, Fiona, MØLLER, Pål, SAMPSON, J., BURN, John, MOESLEIN, Gabriela, CAPELLÁ, G. (gabriel). Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?. _Genetics in Medicine_. 2019. Vol. 21, núm. 8, pàgs. Pp 1878-1879. [consulta: 10 de desembre de 2025]. [Disponible a: https://hdl.handle.net/2445/171448]